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Coronavirus disease 2019 (COVID-19) is a novel and highly contagious disease caused by
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older adults and
patients with comorbidities and immunosuppressive conditions may experience severe
signs and symptoms that can lead to death. This case series assesses the clinical course,
imaging features, and outcomes for 12 patients with COVID-19 and a history of kidney
transplantation. Patients were evaluated for symptoms, laboratory data, imaging find-
ings, and outcomes from February 2020 to April 2020. Fever, cough, and dyspnea were
the most common clinical symptoms, noted in 75% (nine/12), 75% (nine/12), and 41.7%
(five/12) of the patients, respectively. Most of the patients had a normal white blood cell
count, while 33.3% (four/12) had leukopenia and 8.3% (one/12) had leukocytosis. A
combination of consolidation and ground glass opacity was the most predominant (75%)
pattern of lung involvement on computed tomography (CT). Eight patients died of severe
COVID-19 pneumonia and acute respiratory distress syndrome and four were
discharged. All recovered cases had a unilateral peripheral pattern of involvement
limited to only one zone on initial chest CT. It seems that CT imaging has an important
role in predicting COVID-19 outcomes for solid organ transplant recipients. Future
studies with long-term follow up and more cases are needed to elucidate COVID-19
diagnosis, outcome, and management strategies for these patients.
© 2020 Published by Elsevier B.V. on behalf of European Association of Urology.
* Corresponding author. Department of Radiology, Shahid Labbafinejad Hospital, Boostan 9, Pasdaran
Avenue, Tehran, Iran. Tel.: +98 912 3055325.
E-mail address: abr.alireza@yahoo.com (A. Abrishami).1. Case series
1.1. Background
On December 31, 2019, a novel corona virus was extracted
from the respiratory secretions of several patients present-
ing with lower respiratory tract infection of unknown originhttps://doi.org/10.1016/j.eururo.2020.04.064
0302-2838/© 2020 Published by Elsevier B.V. on behalf of European Associain Wuhan, China [1]. While the mortality rate of coronavirus
disease 2019 (COVID-19) is believed to be approximately 5%
[2], older adults and those with an underlying chronic
disease are specifically at high risk of presenting with severe
symptoms, having poorer prognosis, and even developing
fatal conditions [3]. Use of immunosuppressive medications
such as steroids may also be linked to severe manifestationtion of Urology.
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infections such as H1N1 [4].
Solid organ transplant recipients are on long-term
immunosuppressive regimens and are at particular risk of
contracting severe respiratory tract infection and possibly
with atypical presentation [5]. There are currently limited
data on the clinical course, imaging features, and outcomes
for COVID-19 in renal transplant recipients. Although some
studies noted no other outstanding severe disease among
immunosuppressed patients with COVID-19 [6], other
studies revealed that immunocompromised patients may
have an impaired immune response and high levels of viral
load [7].
Here we report clinical and imaging findings for COVID-
19 and outcomes in a group of patients with a functioning
renal transplant under an immunosuppressive regimen.
1.2. Cases
The study cases consisted of 12 patients with a functioning
renal transplant who were admitted to our tertiary hospital
with a confirmed diagnosis of COVID-19 between February
25, 2020 and April 12, 2020.
All subjects met the following inclusion criteria: (1)
symptoms suggestive of COVID-19 pneumonia (ie, fever,
cough, dyspnea, sore throat, myalgia, headache, nausea, or
abdominal pain); (2) positive SARS-CoV-2 nasopharyngeal
sample (polymerase chain reaction–based test); (3) chest
computed tomography (CT) scan suggestive of COVID-19;
and (4) lymphocytopenia (absolute lymphocyte count
<1000) or dyspnea or O2 saturation <93% or respiratory
rate >30/min.
Nine patients were male (75%) and three were female
(25%). The mean age ( standard deviation) of the patients
was 47.66  1.35 (range 29–66) yr. The most common
symptoms were fever, cough, and dyspnea, noted in 75%
(nine/12), 75% (nine/12), and 41.7% (five/12), respectively.
On admission, all patients were on standard triple
immunosuppressive therapy (steroid, calcineurin inhibi-
tor/sirolimus, mycophenolate mofetil/azathioprine). The
medical history of the patients was reviewed for any
chronic conditions other than chronic renal failure. Table 1Table 1 – Demographic and clinical features and outcomes for the 12 
Pt Gender Age (yr) Age of KTx (yr) CMBs Fever C
1 Female 29 8 None + +
2 Male 32 12 HTN + +
3 Male 58 14 None – –
4 Male 38 15 None – +
5 Male 54 18 Asthma + SA + +
6 Male 46 3 None + +
7 Male 66 4 None + –
8 Male 32 17 None + +
9 Male 64 6 None + +
10 Male 64 3 None + +
11 Female 49 17 HTN – +
12 Female 40 16 None + –
KTx = kidney transplantation; CMBs = comorbidities; HTN = hypertension; SA = stab
diarrhea); SO2 = oxygen saturation on room air.shows detailed clinical characteristics of the cases. Leuko-
penia was observed in 33.3% (four/12) and leukocytosis in
8.3% (one/12). C-reactive protein was elevated in 83.3%
(10/12) and creatine phosphokinase in 55% (five/nine). On
admission, mean blood urea nitrogen was 82.9  55.2 mg/dl
and creatinine was 2.30  1.09 mg/dl. Graft function on
admission in terms of estimated glomerular filtration rate
based on the Modification of Diet in Renal Disease equation
was 39.9  24.5 cm3/min. Table 2 lists detailed laboratory
findings.
On admission, the oral steroid was changed to intrave-
nous steroid administration. The immunosuppressive dose
was reduced according to the protocol in our center under
consultation with multidisciplinary team comprising a
nephrologist, urologist, and infectious disease specialist.
Hydroxychloroquine 400 mg stat, Kaletra (lopinavir/ritona-
vir) 400/100 mg twice daily, and suitable intravenous
antibiotics were initiated for all patients. Intravenous
immunoglobulin 1–2 g/kg in segregated doses over 5 d
was administered in the case of hypoxemia and a creatinine
rise with clinical suspicion of kidney transplant rejection.
As a part of our national COVID-19 guidelines, all patients
underwent noncontrast chest CT imaging using a low-dose
protocol. Two expert radiologists with 9 and 18 yr of
experience interpreted the images independently. In the
case of disagreement between the readings, the two
radiologists reassessed the images in order to reach
consensus. The laterality of the disease (unilateral vs
bilateral), the distribution (peripheral vs central, anterior
vs posterior), and the predominant zonal involvement
(upper, middle, lower, or diffuse) were recorded. The
predominant pattern of involvement in each lobe was
assessed and categorized as ground-glass opacity (GGO) or
consolidation. When there was a combination of GGO and
consolidation, the allocation was divided between them
accordingly. The percentage of lobar involvement was
scored using the following system: 0, no involvement; 1,
<25%; 2, 26–50%; 3, 51–75%; and 4, >75% involvement
[8]. The scores for each lobe were summed to calculate the
total lung score (maximum score 20). The final score was
multiplied by five to estimate the percentage lung involve-
ment. The presence of other imaging features was alsopatients.
ough HA Myalgia Dyspnea GIS SO2 (%) Outcome
 – – – – 88 Discharged
 – + + + 85 Discharged
 – – – – 88 Death
 – + + – 84 Death
 – – – – 90 Death
 – – + – 85 Discharged
 – – – – 85 Death
 – – + – 84 Death
 – – + – 90 Death
 – – – – 84 Death
 + – – – 90 Discharged
 – – – – 88 Death
le angina; HA = headache; GIS = gastrointestinal symptoms (abdominal pain/
Table 2 – Baseline laboratory findings.
Patient Summary
1 2 3 4 5 6 7 8 9 10 11 12 (mean  SD)
White blood cell count 2000 5500 3800 5600 12 200 8700 7200 8800 4200 3100 7500 2500 5925  3050
Neutrophil count 1040 4345 2470 4984 11590 6264 5976 7920 3318 2697 6000 2050 4887.83  2934.14
Lymphocyte count 840 1100 1140 560 610 2001 1152 704 798 279 1200 375 896.58  464.81
Eosinophils (%) 3 0 2 0 0 2 0 0 1 2 2 1 –
Hemoglobin (g/dl) 9.1 11.7 15.4 11 9.9 12.4 9.1 11.7 13.6 11.1 15.2 8.5 11.55  2.28
Platelets (103) 131 485 123 148 263 465 160 171 107 54 161 98 197  139
C-reactive protein (mg/l) 17 30 5 61 40 66 24 49 3 31 23 30 31.58  19.76
Lactate dehydrogenase (U/l) 305 384 412 110 506 80 326 641 592 931 898 928 509.41  297.36
Creatinine (mg/dl) 2.99 0.92 1.53 2.55 2.96 1.77 2.50 4.60 1.23 1.50 1.51 3.60 2.3  1.09
Blood urea nitrogen (mg/dl) 85 23 33 119 156 60 145 150 30 39 18 137 82.91 55.16
Aspartate transaminase (U/l) 19 17 25 24 19 26 12 28 37 167 31 12 34.75  42.3
Alanine transaminase (U/l) 6 11 17 8 19 42 14 14 19 96 43 8 24.75  25.52
Alkaline phosphatase (U/l) 92 118 203 205 128 106 90 102 148 204 237 134 147.25  51.52
Albumin (g/l) 3.1 4 3 4.5 3.1 3 3.6 3.2 3.4 2.7 3.3 3.9 3.4  0.51
Na (mEq/l) 138 139 138 137 141 143 141 133 137 133 142 140 138.5  3.2
K (mEq/l) 4.5 3.5 4.1 3.6 3.4 5 5 4.1 4 4.4 3.7 3.4 4.05  0.57
Prothrombin time (s) 10.5 10.6 9.8 11.6 13.3 10 11.7 11.1 9.8 14.8 9.8 9.9 11.07  1.58
Partial thromboplastin time (s) 20 20 20 22 27 20 23 69 20 37 26 20 27.05 14.18
International normalized ratio 1.01 1.06 0.9 1.13 1.3 1.1 1.14 1.07 0.94 1.4 0.9 0.95 1.07  0.15
SD = standard deviation.
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thickening, crazy-paving pattern, reverse halo sign, cystic
changes, presence of cavitations, lymphadenopathy (de-
fined as lymph node with short axis >10 mm), and pleural
and pericardial effusion.
The initial CT scan on admission showed bilateral lung
involvement in eight patients and unilateral involvement in
four. The lower lobes were frequently involved, as observed
in 11/12 of patients (Table 3). A combination of consolida-
tion and GGO was the most predominant (75%) pattern,
followed by GGO only (25%; Fig. 1). In terms of lesion
distribution, a combination of peripheral plus centralTable 3 – Frequency of chest computed tomography scan features in th
Parameter 
Lung involvement Bilateral 
Unilateral 









Axial distribution Peripheral 
Peripheral +
Segmental distribution Posterior 
Anterior 
Diffuse 






Pericardial involvement was the most common. The mean lung
involvement score was 9.5  5.5 out of 20, which gives a
mean estimate of 47.5  27.8% for total lung involvement
(Table 4).
We did not observe cavitation, cystic changes, or
lymphadenopathy in any of the study population. Three
patients had pleural or pericardial effusion or both. Four
patients had a mildly elevated cardiothoracic ratio on chest
CT. Pneumomediastinum was observed in two patients who
had severe changes on chest CT, but neither was intubated
or underwent noninvasive ventilation (NIV) before acquisi-
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Fig. 1 – A 38-yr-old male patient presented with a dry cough and dyspnea and a history of kidney transplantation 15 yr previously. Computed
tomography images show bilateral peripheral ground glass opacity (thin arrows) on the anterior side and an area of bilateral consolidation with air
bronchogram (wide arrows) on the posterior side, predominantly in the lower lobes. Incidental pneumomediastinum is noted (thick-headed arrows).
The patient died after 22 d in hospital.
Table 4 – Chest computed tomography scores for each lobe and
total lungs.
Lobar anatomy Ground glass opacity Consolidation Total score
Right upper lobe 1.5 0.16 1.66
Right middle lobe 1.66 0 1.66
Right lower lobe 1.41 0.91 2.32
Left upper lobe 1.41 0.08 1.49
Left lower lobe 1.58 0.75 2.33
Total lungs 7.58 1.9 9.46
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endpoints, which were death or complete recovery and
discharge. Follow-up chest CT was carried out for three
patients, while a portable chest X-ray was used for follow-
up for the remaining nine. Follow-up imaging revealed
progressive radiologic changes such as bilateral areas of air
space opacity (Fig. 2).
Of the 12 patients, ten were admitted to an intensive care
unit, nine were intubated, eight died of severe COVID-19
pneumonia and acute respiratory distress syndrome (ARDS),
and four were discharged after complete recovery. Three
patients required neither NIV nor intubation. The median
hospital stay was 15 d (interquartile range [IQR] 8.0–21.5),
with a longer stay for patients who died (18.0 d, IQR 12.3–
21.5) than for those who were discharged (7.0 d, IQR 6.0–
28.3), but the difference was not statistically significant.
2. Discussion
Owing to long-term immunosuppressive therapy, kidney
transplant recipients are at higher risk of COVID-19
involvement in comparison to immunocompetent individ-
uals. However, a few studies with small sample sizes have
reported conflicting results for the characteristics of COVID-
19 in these patients. In solid organ transplant recipients, the
clinical presentation, imaging findings, laboratory data, andoutcomes may differ from those for other adults and vary
among patients.
On initial presentation, just one of our 12 cases had
gastrointestinal symptoms; the most typical presentation
was cough and fever, as for other adults [9,10]. Guillen et al
[11] reported on a patient with a history of third kidney
transplant who presented with vomiting and fever as a first
symptom and was finally diagnosed with COVID-19 on
follow-up.
Laboratory findings revealed that although the majority of
COVID-19 patients in the general population have leukopenia
and lymphocytopenia (70%) [12], normal white blood cell
count was a more frequent finding in our series and
leukopenia was detected in one-quarter of our subjects. On
admission, lymphocytopenia was detected in 58.33% of our
patients, whereas all cases had lymphocytopenia in another
study [13]. In contrast to our results, Fishman and Grossi [14]
reported that leukopenia and lymphopenia were the preva-
lent finding in immunocompromised transplant recipients.
According to CT images, the most common pattern of
lung involvement was bilateral involvement with a diffuse
pattern and a posterior segmental distribution. GGO, a
feature highly suggestive of COVID-19, was observed in all
cases and consolidation in the majority of cases. A crazy-
paving pattern was observed in two patients, which is
consistent with late-phase COVID-19. One-third of our cases
had unilateral involvement; in other studies, one case had
bilateral GGO [15] and one of five cases described by Zhang
et al [13] had unilateral involvement.
All the initial CT scan findings were compatible with a
normal immune function except for unilateral involvement
and consolidation, which were slightly more frequent in our
series than in a previous multicenter study of 101 COVID-19
patients [16]. Most patients in the later stages showed
subpleural involvement as a less common finding. As the
disease progresses, other uncommon findings include
pleural/pericardial effusion, lymphadenopathy, cavitation,
Fig. 2 – A 49-yr-old woman presented with a dry cough, sore throat, headache, and a history of kidney transplantation 17 yr previously. (A,B) Computed
tomography (CT) images obtained 3 d after the onset of symptoms show patchy ground-glass opacity in the right inferior lobe with slight central
consolidation (long arrows). (C,D) CT images obtained 25 d after the onset of symptoms with secondary superimposed bacterial pneumonia show
diffuse bilateral ground-glass opacity and consolidation with air bronchogram (wide arrows) predominantly in the upper lobes and bilateral mild
plural effusion (thick-headed arrows). (E,F) CT images obtained 28 d after the onset of symptoms and intravenous antibiotic therapy show evolution of
the area of consolidation with vacuolar signs (small black arrows) in the right upper lobe and fibrotic bands (long arrow) in the right lower lobe. The
patient was discharged after 37 d.
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features in severely ill patients were bilateral multilobar
involvement and subsegmental consolidation [17].
Our study revealed that interlobular septal thickening,
multilobar patterns, consolidative lesions, and a high score for
lung involvement were more frequent among the patients
with poor outcome and complicated cases with ARDS. In
addition, all cases with pleural and pericardial effusion or a
crazy-paving appearance had poor outcome. Interestingly,
two cases had pneumomediastinum as a rare finding on chest
CT at the time of presentation, without any history of
intubation or other predisposing procedures. Patients who
survived had a shorter hospital stay and a unilateral peripheral
pattern limited to only one zone of the lung, with none of the
other findings mentioned for patients with poor outcome.
In conclusion, CT imaging features may have an
important role in predicting COVID-19 outcomes for kidney
transplant recipients. However, the majority of the findings
are similar to those from other adult studies for the general
population.
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Appendix A. Supplementary data
Supplementary material related to this article can be
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